Trial Profile

A Multicenter, Randomized, Open-label, Phase 3 Long-term Safety Study of Topically Applied Sofpironium Bromide (BBI-4000) Gel, 5% and 15% in Subjects With Axillary Hyperhidrosis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 22 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sofpironium bromide (Primary)
Indications Hyperhidrosis
Focus Adverse reactions; Registrational
Acronyms ARGYLE
Sponsors Botanix Pharmaceuticals

Most Recent Events

23 Apr 2021 According to a Brickell Biotech Inc media release,190 patients completed the full study duration of 52 weeks.
23 Apr 2021 Results presented in a Brickell Biotech Inc Media Release.
23 Apr 2021 According to a Brickell Biotech Inc media release, data were presented at the American Academy of Dermatology (AAD) 2021 Virtual Meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com